Biotherapies in large vessel vasculitis

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Large vessel vasculitis (LVV), including giant cell arteritis (GCA) and Takayasu's arteritis (TA), often involves the aorta.
• Behcet's disease (BD) and relapsing polychondritis (RP) can also present with aortic complications.
• Glucocorticosteroids are the primary treatment for LVV, but many patients experience dependence, side effects, or treatment resistance.

Purpose of the Study:

• To review the current therapeutic landscape for large vessel vasculitis.
• To explore the efficacy of established and emerging biologic agents in managing refractory LVV.
• To highlight the potential of targeted therapies for improving patient outcomes.

Main Methods:

• Literature review of current therapeutic strategies for LVV.
• Analysis of clinical data on the use of biologic agents in GCA, TA, BD, and RP.
• Evaluation of treatment responses to anti-tumor necrosis factor-α and anti-IL6-receptor therapies.

Main Results:

• Anti-tumor necrosis factor-α agents show efficacy in Takayasu arteritis and vascular BD but not in GCA.
• Tocilizumab (anti-IL6-receptor antibody) has demonstrated encouraging preliminary results in LVV.
• A significant portion of LVV patients are refractory to or intolerant of conventional immunosuppressive treatments.

Conclusions:

• Biologic agents represent a promising avenue for treating patients with refractory large vessel vasculitis.
• Targeted therapies, such as IL-6 receptor inhibitors, offer new hope for managing complex cases of LVV.
• Further research into novel biologic targeted therapies is crucial for advancing LVV treatment.